Experimental study of therapeutic efficacy of Baicalin in rats with severe acute pancreatitis

Table 1 Improved Schmidt score of pathological changes of the pancreas

Edema	Acinar necrosis(necrotic cells/HPF)		Inflammation and perivascular infiltrate(intralobular or perivascular leukocytes/HPF)		Hemorrhage and fatnecross (focus)
Absent	0	Absent	0	0-1	0	Absent
Focal expansion of interlobular septae	1	1-4	1	2-10	1	1-2
Same as 1 + diffuse expansion of interlobar; Septae/diffuse expansion of interlobar septae	2	5-10	2	11-20	2	3-4
Same as 2 + expansion of interacinar septae	3	11-16	3	21-30	3	5-6
Same as 3 + expansion of intercellular spaces	4	> 16	4	> 30/microabscesses	4	> 7

Table 2 Comparison of ascites/body weight ratio [M (Q_R)]

Groups	3 h	6 h	12 h
Sham operation	0.28 (0.23)	0.44 (0.15)	0.39 (0.22)
Model control	2.02 (0.89)	2.62 (0.97)	2.70 (0.80)
Baicalin treatment	1.00 (1.30)	1.16 (0.73)	2.29 (1.21)
Octreotide treatment	1.43 (0.62)	2.15 (0.88)	2.08 (2.21)

Table 3 Comparison of different indexes of blood [M (Q_R)]

Indexes	Sham operation			Model control			Baicalin treatment			Octreotide treatment
	3 h	6 h	12 h	3 h	6 h	12 h	3 h	6 h	12 h	3 h	6 h	12 h
Amylase	1582	1769	1618	5303	6276	7538	4342	5130	5571	5419	5058	6531
(U/L)	(284)	(362)	(302)	(1373)	(1029)	(2934)	(1496)	(1591)	(2307)	(1670)	(1314)	(2280)
TNF-α	3.90	4.00	5.30	41.44	92.15	65.02	44.93	65.10	47.65	39.30	47.60	54.50
(ng/L)	(3.20)	(1.70)	(3.00)	(37.72)	(23.12)	(26.81)	(45.84)	(27.51)	(25.52)	(30.60)	(16.50)	(41.40)
IL-6	1.8460	1.74	2.04	5.44	6.82	5.36	3.03	2.88	2.83	2.65	3.08	2.46
(ng/L)	(0.35)	(0.84)	(0.82)	(1.03)	(0.81)	(0.75)	(0.87)	(1.39)	(0.60)	(1.37)	(1.210)	(1.35)
MDA	9.90	16.50	16.50	36.30	39.70	54.35	21.90	23.80	36.00	29.60	33.00	40.30
(nmol/mL)	(9.90)	(13.20)	(13.20)	(13.40)	(9.90)	(19.00)	(13.45)	(14.60)	(11.60)	(18.60)	(9.90)	(16.80)

Table 4 Comparison of serum PLA2 content (mean ± SD)

Groups	3 h	6 h	12 h
Sham operation	14.62 ± 3.02	17.49 ± 3.82	19.02 ± 5.07
Model control	76.10 ± 16.70	101.46 ± 14.67	105.33 ± 18.10
Baicalin treatment	56.25 ± 22.43	67.91 ± 20.61	66.86 ± 22.10
Octreotide treatment	74.37 ± 19.94	63.13 ± 26.31	53.63 ± 12.28

Table 5 Comparison of pathological lesion score for pancreas (M (Q_R))

Groups	3 h	6 h	12 h
Sham operation	0.00 (1.00)	0.00 (1.00)	0.00 (1.00)
Model control	8.00 (2.00)	9.00 (3.00)	10.50 (1.50)
Baicalin treatment	7.00 (1.50)	7.00 (3.00)	9.00 (4.00)
Octreotide treatment	7.00 (2.00)	6.00 (2.00)	8.00 (2.00)

Table 6 Comparison of therapeutic efficacy of octreotide and Baicalin

Therapeutic efficacy	Curative
	Baicalin	Octreotide
Improve survival rate	++	++
Decrease ascites volume	++	+
Decrease amylase	+	+
Decrease TNF-α	+	++
Decrease IL-6	++	+
Decrease MDA	+	++
Decrease PLA2	++	+
Protect pancreatic tissue	++	++

++: Represents significant effect; +: Represents normal effect; -: No effect.